54 research outputs found

    Anti-tuberculosis potential of bruceine: An in silico approach

    Get PDF
    Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. The bacterial enzyme pantothenate synthetase (PS) catalyzes the synthesis of pantothenate, a precursor of coenzyme A. Hence, targeting PS is a potential mechanism in the development of anti-tuberculosis drugs. Bruceine, a highly oxygenated natural quassinoid molecule, is isolated from plants of the Simaroubaceae family. The anti-tuberculosis potential of eleven bruceine (A, B, C, D, E, G, H, I, J, K and L) has been investigated by in silico approach. The molecular docking (AutodockVina) and drug-likeness (Lipinski’s rule of five) analyses identified bruceine D as a potential inhibitor. Further, it has shown six hydrogen bond interactions with the key amino acids residues of the target protein, Tyr82, His135, Lys160 and Asp161. The ring-A and -D has contributed two hydrogen bonds, while one each from ring-C and -E. The results reveal that bruceine D possesses druglikeness property and binding energy of -9.3 kcal/mol. The binding score similar to pantoyl adenylate suggests chemical modifications to enhance the protein inhibition potency. Bruceine D has a great potential to inhibit PS and could contribute to the tuberculosis drug discovery process

    Computational Intelligence for Analysing the Mechanical Properties of AA 2219 - (B4C + h-BN) Hybrid Nano Composites Processed by Ultrasound Assisted Casting

    No full text
    The computational intelligence tool has major contribution to analyse the properties of materials without much experimentation. The B4 C particles are used to improve the quality of the strength of materials. With respect to the percentage of these particles used in the micro and nano, composites may fix the mechanical properties. The different combinations of input parameters determine the characteristics of raw materials. The load, content of B4 C particles with 0%, 2%, 4%, 6%, 8% and 10% will determine the wear behaviour like CoF, wear rate etc. The properties of materials like stress, strain, % of elongation and impact energy are studied. The temperature based CoF and wear rate is analysed. The temperature may vary between 30°C, 100°C and 200°C. In addition, the CoF and wear rate of materials are predicted with respect to load, weight % of B4 C and nano hexagonal boron nitride %. The intelligent tools like Neural Networks (BPNN, RBNN, FL and Decision tree) are applied to analyse these characteristics of micro/nano composites with the inclusion of B4 C particles and nano hBN % without physically conducting the experiments in the Lab. The material properties will be classified with respect to the range of input parameters using the computational model

    Anti-tuberculosis potential of bruceine: An in silico approach

    No full text
    782-787Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. The bacterial enzyme pantothenate synthetase (PS) catalyzes the synthesis of pantothenate, a precursor of coenzyme A. Hence, targeting PS is a potential mechanism in the development of anti-tuberculosis drugs. Bruceine, a highly oxygenated natural quassinoid molecule, is isolated from plants of the Simaroubaceae family. The anti-tuberculosis potential of eleven bruceine (A, B, C, D, E, G, H, I, J, K and L) has been investigated by in silico approach. The molecular docking (AutodockVina) and drug-likeness (Lipinski’s rule of five) analyses identified bruceine D as a potential inhibitor. Further, it has shown six hydrogen bond interactions with the key amino acids residues of the target protein, Tyr82, His135, Lys160 and Asp161. The ring-A and -D has contributed two hydrogen bonds, while one each from ring-C and -E. The results reveal that bruceine D possesses druglikeness property and binding energy of -9.3 kcal/mol. The binding score similar to pantoyl adenylate suggests chemical modifications to enhance the protein inhibition potency. Bruceine D has a great potential to inhibit PS and could contribute to the tuberculosis drug discovery process
    corecore